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INTRODUCTION
Sleep-related problems in Parkinson’s disease (PD) have re-
ceived increasing attention in past years due to their occur-
rence in early stages of the disease, as well as their clinical in-
fluence on morbidity, disability, and the health-related quality 
of life (HRQoL) of patients with advanced disease.1-4 Par-
kinson’s Disease Sleep Scale (PDSS) is a patient-reported in-
strument recommended by the Movement Disorder Society 
task force, and is designed to rate overall sleep problems in 
the PD population.5,6 A revision of PDSS (PDSS-2) was re-
cently published that places particular emphasis on improv-
ing scale properties and encompassing nocturnal symptoms 
that were not previously included (e.g., restless leg syndrome, 
sleep apnea, akinesia, and nocturnal pain).7 PDSS-2 has been 
successfully applied in several clinical trials as a reliable pa-
tient-reported outcome measure.7-11 This prompted us to trans-
late and adapt PDSS-2 to Korean individuals and evaluate its 
clinimetric properties in the assessment of sleep disturbances 
among Korean-speaking patients with PD. 
This study also sought to determine the discriminatory 
capacity of the new Korean version of PDSS-2 (K-PDSS-2) 
by conducting latent class analysis (LCA) to characterize sub-
types of sleep disturbance in PD. Several studies have applied 
LCA in PD populations to address depression-anxiety sub-
types12,13 and neurocognitive subtypes.14 The potential causes 
of sleep disturbances vary widely, and have been suggested 
to include primary insomnia, depression, rapid-eye-move-
ment sleep-behavior disorder (RBD), restless leg syndrome, 
nocturnal motor symptoms, antiparkinsonian drug side ef-
fects, nocturia, and sleep-related breathing disorders, all of 
which frequently co-occur.1,3,4 However, few studies have at-
tempted to empirically outline the clinical heterogeneity of 
sleep-related problems in patients with PD. LCA has previous-
ly been used to identify subtypes of sleep disturbance in pa-
tients with Alzheimer’s disease.15 An empirical search for latent 
homogeneous subgroups of patients who experience similar 
patterns in sleep-related problems and nocturnal disabilities 
could help to elucidate the pathophysiology of these condi-
tions and lead to the development of more-targeted man-
agement strategies. To our knowledge, the present study is the 
first to document the application of an LCA approach for 
identifying subtypes of sleep disturbance in patients with PD.
METHODS
Subjects
This study, which had a test–retest design, recruited patients 
who met the United Kingdom Parkinson’s Disease Society 
Brain Bank criteria for PD between August 2014 and Sep-
tember 2015 from 31 different movement-disorder centers in 
Korea. All of the patients included in the study were required 
to be on a known and stable antiparkinsonian medication 
for the 4 weeks prior to study commencement. Patients with 
Background and Purpose  This study aimed to determine the clinimetric properties of the 
Korean version of Parkinson’s Disease Sleep Scale-2 (K-PDSS-2) and whether distinct subtypes 
of sleep disturbance can be empirically identified in patients with Parkinson’s disease (PD) us-
ing the cross-culturally validated K-PDSS-2.
Methods  The internal consistency, test–retest reliability, scale precision, and convergent validi-
ty of K-PDSS-2 were assessed in a nationwide, multicenter study of 122 patients with PD. Latent 
class analysis (LCA) was used to derive subgroups of patients who experienced similar patterns 
of sleep-related problems and nocturnal disabilities.
Results  The total K-PDSS-2 score was 11.67±9.87 (mean±standard deviation) at baseline and 
12.61±11.17 at the retest. Cronbach’s α coefficients of the total K-PDSS-2 scores at baseline and 
follow-up were 0.851 and 0.880, respectively. The intraclass correlation coefficients over the 
2-week study period ranged from 0.672 to 0.848. The total K-PDSS-2 score was strongly corre-
lated with health-related quality of life measures and other corresponding nonmotor scales. 
LCA revealed three distinct subtypes of sleep disturbance in the study patients: “less-troubled 
sleepers,” “PD-related nocturnal difficulties,” and “disturbed sleepers.”
Conclusions  K-PDSS-2 showed good clinimetric attributes in accordance with previous stud-
ies that employed the original version of the PDSS-2, therefore confirming the cross-cultural 
usefulness of the scale. This study has further documented the first application of an LCA ap-
proach for identifying subtypes of sleep disturbance in patients with PD.
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secondary parkinsonism, atypical parkinsonian syndrome, 
concomitant treatment with hypnotics and/or antipsychotics, 
a score of <20 on the Korean version of the Mini-Mental State 
Examination (K-MMSE), or those aged 40 years or younger at 
disease onset were excluded. Written informed consent was 
obtained from all of the study participants, and the study 
protocol was approved by the Institutional Review Boards at 
the participating centers (IRB No. 2014-08-029). This inves-
tigation formed part of a larger nationwide program study-
ing the cultural adaptation and clinimetric validation of dif-
ferent scales for nonmotor manifestations of PD in Korea.2,16
Translation and cross-cultural adaptation of 
K-PDSS-2 
The original questionnaire was translated from English into 
Korean by two independent bilingual translators. A transla-
tion committee consisting of movement disorder experts re-
viewed both translated versions to reconcile a single forward-
translated version, which was then backward translated from 
Korean to English by another independent bilingual transla-
tor who was blinded to the previous steps. The back-translat-
ed version was compared to the original English question-
naire, and forward–backward amendments were made by 
the translation committee based on consensus. The amend-
ed translated version was pretested on four patients with PD 
who were not a part of this study in order to assess its inter-
pretation of items, ease of comprehension, and cross-cultur-
al relevance. These processes produced the final harmonized 
version of the K-PDSS-2 instrument.5,9,11
Study procedure
Both demographics and clinical data were collected for all 
study patients. The overall severity of disease was evaluated 
using Hoehn and Yahr (H-Y) staging and parts I–III of the 
Unified Parkinson’s Disease Rating Scale (UPDRS). The mo-
tor phenotype was classified based on the ratio of UPDRS 
items proposed by Jankovic et al.17 We administered the Ko-
rean version of the Non-Motor Symptoms Scale (K-NMSS) 
consisting of the following nine domains to quantify the range 
of nonmotor manifestations of the disease: cardiovascular, 
sleep/fatigue, mood, perceptual problems, attention/mem-
ory, gastrointestinal, urinary, sexual function, and miscella-
neous.18 The disease-specific HRQoL was investigated using 
the Korean version of the 39-item Parkinson’s Disease Ques-
tionnaire (K-PDQ-39).19 The Korean version of the Mont-
gomery-Åsberg Depression Rating Scale (K-MADRS) was 
used to assess depressive symptoms, while K-MMSE and the 
Korean version of the Montreal Cognitive Assessment (Mo-
CA-K) were administered to evaluate cognitive function.20,21 
Sleep-related problems and nocturnal disabilities among the 
study patients were globally addressed using the K-PDSS-2 
instrument obtained from the above-described cross-cultural 
adaptation process. The test–retest reliability was measured 
by applying the K-PDSS-2 questionnaire twice over an inter-
val from 10 to 14 days.
Statistical analysis
Clinimetric properties were statistically evaluated using IBM 
SPSS (version 19, IBM Corporation, Armonk, NY, USA) for 
internal consistency, test–retest reliability, convergent validi-
ty, and scale precision for measurement errors. Cronbach’s α 
coefficients for total scores and item-total correlations for 
individual items were calculated to assess internal consisten-
cy.5 Cronbach’s α coefficients >0.70 and item-total correla-
tion coefficients >0.30 were used to tentatively define an ac-
ceptable level of consistency.9,11,16 Test–retest reliability was 
measured with the intraclass correlation coefficient (ICC) us-
ing a two-way random model and a criterion of >0.60.7,22 The 
scale precision for measurement errors was tested through the 
standard error of the mean (SEM) using the ICC as the reli-
ability coefficient. The measurement errors of K-PDSS-2 
were considered sufficiently low if the SEM was less than half 
of the standard deviation (SD).7,9 Convergent validity with the 
K-NMSS sleep/fatigue domain score and other nonmotor 
measures of PD were evaluated using the Spearman rank-order 
correlation coefficient (rs), with a value of rs>0.40 considered 
to indicate a moderate or stronger correlation.11,16 The Jonck-
heere-Terpstra test for trend detection was used to evaluate the 
relationship between K-PDSS-2 total scores and the H-Y 
stages of the study patients, and p values <0.05 were consid-
ered to reflect statistical significance.
The discriminatory capacity of the K-PDSS-2 instrument 
was statistically assessed using LCA, which identifies classes 
of patients with similar patterns of sleep disturbances. A poly-
tomous-variable LCA was conducted with the open-source 
statistical software R (version 3.4.1, R Foundation for Statis-
tical Computing, Vienna, Austria) using the R package dep-
mixS4 (version 1.3-3).23 The discrete model fit was assessed 
based on the interpretability, parsimony of latent classes, 
Akaike information criterion, and Bayesian information cri-
terion statistics.12,14 Demographics and clinical differences 
were compared among identified latent classes using the chi-
square test or the Kruskal-Wallis test followed by post-hoc 
comparisons with Bonferroni-corrected Mann-Whitney U 
tests, as appropriate.
RESULTS
Table 1 presents demographics and clinical data of the 122 
patients enrolled in this study. At the baseline evaluation, the 
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K-PDSS-2 score was 11.67±9.87 (mean±SD), with a median 
of 9 and an interquartile range (IQR) of 4–16. Most (97.5%, 
n=119) of the 122 study patients who completed the baseline 
evaluation also participated in the retest K-PDSS-2 evalua-
tion, in which the score was 12.61±11.67, with a median of 
10 and an IQR of 4–17. In terms of internal consistency, the 
item-total correlation coefficient ranged from 0.169 to 0.739 
at baseline and from 0.138 to 0.746 at the retest. All items ex-
cept for item 8 (nocturia) satisfied the criterion of the item-
total correlation coefficient (>0.30; Table 2). Cronbach’s α 
coefficients for the K-PDSS-2 total scores at baseline and the 
retest were 0.851 and 0.880, respectively, thereby meeting the 
standard established for internal consistency (Cronbach’s α 
>0.70; Table 3). With regards to the test–retest reliability over 
the interval from 10 to 14 days, the ICCs ranged from 0.672 
(item 4) to 0.848 (item 7), with ICC >0.60 for all items (Table 
2). The ICC of the K-PDSS-2 total score was 0.867, and 
hence exceeded the threshold of 0.60. The scale precision as 
determined by the SEM was 3.60, therefore also meeting 
the criterion (<½SD=4.94).
Table 3 lists the coefficients for the correlations between K-
PDSS-2 and the range of clinical rating scales of PD used to 
assess convergent validity. The total K-PDSS-2 score showed 
significant correlations with the K-PDQ-39 summary index 
(rs=0.496) and K-MADRS score (rs=0.523), and was strongly 
correlated with the total K-NMSS score (rs=0.552) and the 
scores in some of the corresponding K-NMSS domains. As 
expected, the strongest correlation among K-NMSS domains 
was observed for the K-NMSS sleep/fatigue domain (rs= 
Table 1. Demographics and clinical characteristics of the study pa-
tients with Parkinson’s disease
Characteristic Value (n=122)
Age, years 66.55±8.64 [60–73]
Sex
Male 62 (50.8)
Female 60 (49.2)
Disease duration, months 45.82±46.51 [30–72]
Motor subtype
Tremor-dominant 32 (26.2)
Intermediate 13 (10.7)
PIGD 77 (63.1)
Present medication use
LEDD, mg/day 371.92±401.95 [0–600]
Levodopa 99 (81.2)
Dopamine agonists 61 (50.0)
COMT inhibitors 3 (2.5)
MAO inhibitors 23 (18.9)
Amantadine 31 (25.4)
Anticholinergics 14 (11.5)
Acetylcholinesterase inhibitors 5 (4.1)
Antidepressants 16 (13.1)
Hoehn and Yahr stage 2.16±0.67 [2–2.5]
Stage 1 16 (13.1)
Stage 2 57 (46.7)
Stage 3 47 (38.5)
Stage 4 or 5 2 (1.6)
Data are mean±standard deviation [interquartile range] or n (%) values.
COMT: catechol-O-methyltransferase, LEDD: levodopa equivalent daily 
dosage, MAO: monoamine oxidase, PIGD: postural instability and gait 
difficulty.
Table 2. Clinimetric validation-related statistics
K-PDSS-2 item
Baseline Item-total 
correlation
(baseline)
Retest Item-total 
correlation
(retest)
ICC
Mean
Median 
[IQR]
Mean
Median 
[IQR]
Bad sleep quality (item 1) 1.15 1 [0–2] 0.374 1.08 1 [0–2] 0.340 0.800
Difficulties falling asleep (item 2) 0.88 0 [0–2] 0.343 0.94 0 [0–2] 0.454 0.806
Difficulties staying asleep (item 3) 1.34 1 [0–3] 0.429 1.40 1 [0–2] 0.468 0.839
Restlessness of legs or arms at night (item 4) 0.49 0 [0–1] 0.578 0.70 0 [0–1] 0.609 0.672
Urge to move legs or arms (item 5) 0.44 0 [0–0] 0.623 0.68 0 [0–0] 0.687 0.750
Distressing dreams at night (item 6) 0.61 0 [0–1] 0.502 0.62 0 [0–1] 0.478 0.694
Distressing hallucinations at night (item 7) 0.34 0 [0–0] 0.564 0.37 0 [0–0] 0.518 0.848
Nocturia (item 8) 1.99 2 [1–3] 0.169 2.07 2 [1–3] 0.138 0.804
Uncomfortable and immobility at night (item 9) 0.51 0 [0–0] 0.662 0.55 0 [0–0] 0.728 0.685
Pain in arms or legs (item 10) 0.70 0 [0–1] 0.739 0.76 0 [0–1] 0.746 0.746
Muscle cramps in arms or legs (item 11) 0.75 0 [0–1] 0.578 0.82 0 [0–1] 0.669 0.753
Painful posturing in the morning (item 12) 0.32 0 [0–0] 0.600 0.35 0 [0–0] 0.640 0.755
Tremor on waking (item 13) 0.61 0 [0–1] 0.451 0.58 0 [0–0] 0.565 0.696
Tired and sleepy after waking in the morning (item 14) 1.17 0 [0–2] 0.448 1.20 1 [0–2] 0.609 0.765
Snoring or difficulties in breathing (item 15) 0.39 0 [0–0] 0.460 0.48 0 [0–0] 0.548 0.717
Total score 11.67   9 [4–16] Cronbach’s α=0.851 12.61 10 [4–17] Cronbach’s α=0.880 0.867
ICC: intraclass correlation coefficient, IQR: interquartile range, K-PDSS-2: Korean version of Parkinson’s Disease Sleep Scale-2.
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0.544; Table 3). There was also a significant relationship be-
tween the total K-PDSS-2 score and H-Y stage (standardized 
Jonckheere-Terpstra statistic=2.091, p=0.037).
LCAs were conducted with K-PDSS-2 items to identify 
subtypes of sleep problems, trialing solutions involving from 
one to seven latent classes. A three-class solution was found 
to be the most-parsimonious model based on interpretability 
and fit indices (Table 4). Symptom profiles of the 3 subtypes 
of sleep disturbance are presented graphically in Fig. 1 as the 
predicted responses of the study patients in each class on a 
range of 15 items of K-PDSS-2. Across all study participants 
(n=122), 78 patients (63.9%) were assigned to class 1, the larg-
est latent class. The symptom profiles of class 1 were charac-
terized by overall low predicted responses on K-PDSS-2 items 
(Fig. 1), and so individuals in class 1 were labeled as “less-
troubled sleepers.” Twenty-two patients (18.0%) were classi-
fied into class 2, with high predicted responses for the rest-
lessness of legs or arms at night (item 4), urge to move legs or 
arms (item 5), distressing dreams at night (item 6), distressing 
hallucinations at night (item 7), pain in arms or legs (item 10), 
muscle cramps in arms or legs (item 11), and tremor on wak-
ing (item 13). Since most of these items have been described 
as PD symptoms at night and motor symptoms at night in 
previous factor analyses,7,9 class 2 was labeled “PD-related 
nocturnal difficulties.” Finally, 22 patients (18.0%) were as-
signed to class 3, which was profiled by marked predicted re-
sponses in bad sleep quality (item 1), difficulties falling asleep 
(item 2), difficulties staying asleep (item 3), and nocturia 
(item 8). Since most of these items have indicated disturbed 
sleep or fragmented sleep in previous factor-analysis stud-
ies,7,9,11 individuals in class 3 were labeled as “disturbed sleep-
ers” (Fig. 1).
Table 5 compares demographics and clinical variables among 
the three classes. Group differences based on the Kruskal-
Wallis test were found across age, total K-PDSS-2 score (both 
at baseline and the retest), K-PDQ-39 summary index, UP-
DRS part I score, K-MADRS score, total K-NMSS score, and 
scores in four K-NMSS domains (sleep/fatigue, mood, atten-
tion/memory, and urinary domains). Post-hoc analysis of be-
tween-group differences indicated that the patients in class 3 
tended to be younger and have a higher total K-NMSS score, 
K-NMSS sleep/fatigue domain score, K-NMSS attention/
memory domain score, and K-PDQ-39 summary index than 
those in class 1. Class 3 patients also showed a higher NMSS 
urinary domain score compared with those in class 1 or 2. 
Compared to class 1 patients, those in classes 2 and 3 showed 
a markedly higher UPDRS part I score, K-MADRS score, and 
K-NMSS mood domain score. There were no significant dif-
ferences in sex, disease duration, motor phenotype, levodopa 
equivalent daily dosage, use of antiparkinsonian medication, 
or UPDRS part II or III scores between the three classes.
DISCUSSION
The purpose of the current study was twofold: to determine 
1) the clinimetric properties of the K-PDSS-2 and 2) whether 
distinct subtypes of sleep disturbance can be distinguished 
among patients with PD on the basis of the validated K-PDSS- 
2 instrument.
Table 4. Model-fit indices in latent class analysis with one to seven 
derived classes 
Number 
of classes
AIC BIC Log-likelihood
Smallest 
class size (%)
1 3873.52 4041.77 -1876.76 122 (100.00)
2 3706.43 4045.71 -1732.21 34 (24.59)
3 3659.52 4169.86 -1647.76 22 (17.19)
4 3727.88 4409.25 -1620.94 12 (8.2)
5 3792.90 4645.33 -1592.45 11 (6.6)
6 3892.84 4916.31 -1581.42 8 (3.3)
7 3943.22 5137.73 -1545.61 9 (4.9)
AIC: Akaike information criterion, BIC: Bayesian information criterion.
Table 3. Convergent validity of K-PDSS-2 with other motor and non-
motor measurements and patient-perceived quality of life 
Nonmotor measurement Value rs p
UPDRS part I score 2.00±1.99 0.377 <0.001*
UPDRS part II score 7.77±6.00 0.405 <0.001*
UPDRS part III score 20.34±10.94 0.211 0.020*
K-MMSE score 27.43±2.26 -0.145 0.111
MoCA-K score 23.03±4.26 -0.123 0.182
K-MADRS score 9.46±8.26 0.523 <0.001*
K-NMSS total score 34.17±25.12 0.552 <0.001*
Cardiovascular (including falls) 1.00±1.58 0.204 0.024*
Sleep/fatigue 5.84±6.13 0.544 <0.001*
Mood 7.43±8.28 0.416 <0.001*
Perceptual problems 0.59±2.00 0.175 0.054
Attention/memory 3.67±4.36 0.405 <0.001*
Gastrointestinal 2.68±4.47 0.094 0.303
Urinary 8.05±8.25 0.422 <0.001*
Sexual function 2.41±5.02 0.169 0.062
Miscellaneous 2.58±3.41 0.113 0.216
K-PDQ-39 summary index 31.17±26.23 0.496 <0.001*
Data are mean±standard deviation values.
*p<0.05. p values are from the Spearman correlation test.
K-MADRS: Korean version of the Montgomery-Åsberg Depression Rat-
ing Scale, K-MMSE: Korean version of the Mini-Mental State Examination, 
K-NMSS: Korean version of the Non-Motor Symptoms Scale, K-PDQ-39: 
Korean version of the 39-item Parkinson’s Disease Questionnaire, K-
PDSS-2: Korean version of Parkinson’s Disease Sleep Scale-2, MoCA-K: 
Korean version of the Montreal Cognitive Assessment, rs: Spearman 
rank-order correlation coefficient, UPDRS: Unified Parkinson’s Disease 
Rating Scale.
www.thejcn.com  71
Yang HJ et al. JCN
Overall, the cross-cultural adaptation of the K-PDSS-2 in-
strument developed using a structured translation and re-
view processes exhibited satisfactory clinimetric attributes. 
Similar to the original PDSS-2 validation study, we found 
that the new instrument had good internal consistency and 
good test–retest reliability.7,23 The scale precision of the K-
PDSS-2 on measurement error was acceptable in terms of 
the SEM value, which was less than half the SD.7,9 The SEM 
of K-PDSS-2 of our study (3.60 <½SD=4.94) was comparable 
to that found in the original PDSS-2 validation study (3.98< 
½SD=4.45)7 and the study by the Hungarian group (2.459< 
½SD=5.404).9
The convergent validity of K-PDSS-2 was well supported by 
its statistical correlations with other clinical measures. Consis-
tent with the findings of previously published analyses, the 
sleep-related problems and nocturnal disabilities as measured 
herein with K-PDSS-2 increased with advancing disease se-
verity according to H-Y stages.9,24 Higher K-PDSS-2 scores 
were significantly correlated with worse K-PDQ-39 scores, 
indicating a relationship between HRQoL and sleep distur-
bance in PD patients. This finding corroborates previous re-
ports of significant correlations between PDSS-2 scores and 
the HRQoL as measured via PDQ-39 or its subdomains.7-9,11,25 
It is important to note that we found no significant correla-
tion between K-PDSS-2 and neurocognitive performance as 
assessed by both MoCA-K and K-MMSE, whereas depres-
sion as assessed by K-MADRS was closely related to the total 
K-PDSS-2 score. Our results are consistent with two other 
groups finding no significant correlation between the PDSS-2 
total score and cognitive outcomes assessed using the origi-
nal MoCA9 and MMSE11 instruments.
Using LCA, we were able to classify sleep disturbances in 
patients with PD into three latent groups: one baseline sub-
type (class 1), which covered approximately two-thirds of the 
study patients, and two subtypes (classes 2 and 3) associated 
with increased sleep disturbances. One remarkable LCA find-
ing was that the three latent classes did not directly parallel all 
15 K-PDSS-2 items in terms of severity (i.e., mild, moderate, 
and severe). Instead, the predicted item responses (Fig. 1) 
showed that patients in class 2 were more likely to experience 
more PD-related nocturnal symptoms, whereas patients in 
class 3 were more likely to report general sleep difficulties 
than patients in the other subtypes. Our LCA outcomes indi-
cated that sleep disorders in patients with PD are more com-
plicated than simply the degree of severity of sleep disturbances; 
instead, there are different subgroups of patients with sleep dis-
turbances, including those with PD-specific or general sleep 
difficulties. 
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  Class 2: PD-related nocturnal disturbance
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Fig. 1. Predicted symptom profiles of K-PDSS-2 item responses for the sleep-disturbance subtypes based on latent class analysis. K-PDSS-2: Ko-
rean version of Parkinson’s Disease Sleep Scale-2, PD: Parkinson’s disease.
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In a recent review, Diederich and McIntyre3 proposed cat-
egorizing sleep problems in PD into 1) primary causes relat-
ing to degeneration of the brainstem regulatory center and 
impaired thalamocortical arousal, 2) secondary causes in-
cluding motor symptoms, nocturnal dyskinesia, and dysauto-
nomia, 3) tertiary causes mainly due to medication, and 4) oth-
er causes including depression, cardiac, and pulmonary 
comorbidity. Louter et al.1 also suggested three main sub-
groups of sleep disorders in patients with PD: 1) primary 
sleep symptoms caused by neurodegeneration in sleep-regu-
lating regions, 2) nocturnal disturbances due to PD symp-
toms, and 3) medication-related sleep disorders. Our study 
empirically characterized the underlying structure of sleep dis-
turbances in PD that have been and continue to be observed 
routinely by movement disorder experts and clinical neurolo-
gists in practice. The present LCA results suggested that pa-
tients in class 3 can suffer from neurodegeneration in sleep-
regulating regions, whereas patients in class 2 manifest with 
PD-related nocturnal disturbances.1,3,4 Since the K-PDSS-2 in-
strument did not directly address the medications taken by pa-
tients, medication-related sleep problems might not have been 
sufficiently captured.
It is particularly interesting that the differences between 
groups of motor symptoms as assessed by UPDRS parts II 
and III remained small. In contrast, patients identified as be-
ing in either class 2 or 3 had more-severe nonmotor symp-
toms. Our findings of a discrepancy between motor and non-
motor symptoms in relation to sleep-disturbance subtypes are 
consistent with those of several data-driven subtyping studies 
in PD that have found patients experiencing PD motor symp-
toms of similar severities exhibiting considerable differences 
in the severities of their nonmotor symptoms.26-29
Table 5. Demographics and clinical characteristics of study patients in three sleep-disturbance-related latent classes
Variable
Class 1:  
less-troubled sleepers
Class 2: 
PD-related nocturnal difficulties
Class 3: 
disturbed sleepers
χ2 p
Patients (%) 78 (63.9) 22 (18)�� 22 (18.0)
Age, years 68.06±8.07 65.41±8.68 62.32±9.35 6.879 0.032*
Sex, male 40 (51.3) 10 (45.5) 12 (54.6) 0.382 0.826
Disease duration, months 41.71±40.57 49.36±42.03 56.86±66.79 0.922 0.631
Hoehn and Yahr stage 2.14±0.68 2.182±0.61 2.182±0.68 0.652 0.722
LEDD, mg/day 352.33±379.97 441.23±440.88 372.08±448.01 0.817 0.665
UPDRS part I score 1.37±1.58 2.93±2.08 2.55±1.65 17.210 <0.001*†
UPDRS part II score 6.73±5.34 8.82±6.09 8.82±6.52 4.591 0.101
UPDRS part III score 18.90±9.71 22.52±13.38 20.43±12.39 0.806 0.668
K-MMSE score 27.45±2.37 26.91±2.60 27.91±1.27 1.283 0.527
MoCA-K score 23.09±4.46 22.30±4.00 23.45±3.86 0.925 0.630
K-MADRS score 7.03±8.05 13.91±7.52 13.64±6.16 27.408 <0.001*†
K-NMSS total score 29.33±26.23 36.77±17.39 48.73±22.23 16.448 <0.001*
Cardiovascular (including falls) 1.01±1.61 0.86±1.42 1.09±1.69 0.115 0.944
Sleep/fatigue 4.67±6.11 6.32±5.90 9.50±5.06 19.196 <0.001*
Mood 5.62±7.02 10.36±7.08 10.95±11.37 15.647 <0.001*†
Perceptual problems 0.49±1.86 1.41±3.02 0.14±0.47 4.959 0.084
Attention/memory 2.86±3.64 3.95±4.79 6.23±5.34 11.696 0.003*
Gastrointestinal 3.06±5.16 1.27±1.80 2.73±3.47 1.581 0.454
Urinary 7.10±8.49 6.64±5.39 12.82±8.34 8.986 0.011*‡
Sexual function 2.18±5.05 3.50±6.44 2.14±3.00 1.855 0.396
Miscellaneous 2.45±3.47 2.45±3.64 3.14±3.04 1.096 0.578
K-PDQ-39 summary index 24.92±23.03 39.10±30.44 45.73±25.98 15.216 <0.001*
K-PDSS-2 total score (baseline) 6.03±4.44 20.50±10.61 22.86±6.74 74.514 <0.001*†
K-PDSS-2 total score (retest) 7.78±7.41 19.57±13.06 22.64±10.19 40.858 <0.001*†
Data are n (%) or mean±standard deviation values. p values are from the chi-square test or the Kruskal-Wallis test followed by post-hoc comparisons 
with Bonferroni-corrected Mann-Whitney tests.
*Significant difference between classes 1 and 3, †Significant difference between classes 1 and 2, ‡Significant difference between classes 2 and 3.
K-MADRS: Korean version of the Montgomery-Åsberg Depression Rating Scale, K-MMSE: Korean version of the Mini-Mental State Examination, K-
NMSS: Korean version of the Non-Motor Symptoms Scale, K-PDQ-39: Korean version of the 39-item Parkinson’s Disease Questionnaire, K-PDSS-2: 
Korean version of Parkinson’s Disease Sleep Scale-2, LEDD: levodopa equivalent daily dosage, MoCA-K: Korean version of the Montreal Cognitive As-
sessment, PD: Parkinson’s disease, UPDRS: Unified Parkinson’s Disease Rating Scale. 
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It is important to note the potential limitations of this study. 
First, our classification of sleep disturbances was based on the 
K-PDSS-2 instrument, which does not include items related 
to RBD-related nocturnal motor features.8,30 The validity of 
this subtyping has not been tested using polysomnography, 
sleep latency testing, or actigraphy.31,32 RBD, obstructive sleep 
apnea, or other sleep-related respiratory disturbances can ac-
count for some instances of sleep disturbance observed in 
class 3, warranting further evaluation by objective testing 
methods such as polysomnography. The second limitation 
is that our study included only patients with K-MMSE scores 
≥20 at the time of registration, and the mild cognitive im-
pairments in PD could go unrecognized if screening is per-
formed using MMSE scores.33 Third, convergent validity was 
only tested against the corresponding K-NMSS domain (do-
main 2 of K-NMSS), and not against other generic sleep 
scales such as the Pittsburgh Sleep Quality Index or the Wis-
consin Sleep Questionnaire.6,34 Fourth, our study did not de-
termine the optimal cutoff score for K-PDSS-2. No such in-
formation is provided for Korean patients with PD, and thus 
further studies are needed to address the cutoff value for the 
K-PDSS-2 instrument.10,24 Another drawback of our study is 
that measure of daytime sleep disturbances (e.g., excessive 
daytime sleepiness) and related assessment instruments were 
not utilized.
In conclusion, the K-PDSS-2 instrument demonstrated 
clinimetric reliability and validity, indicating that it is a suit-
able tool for measuring nocturnal disturbances and sleep 
disorders in Korean patients with PD. Moreover, using a data-
driven approach, we were able to identify subtypes of sleep 
disturbance in patients with PD. The validity of our LCA-de-
rived subtypes was supported by distinct differences in demo-
graphics and clinical features between the groups. We expect 
our findings to be useful in both research and clinical eval-
uations of sleep disturbances in PD.
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